Manipulation of Hematopoietic Stem Cells for Regenerative Medicine

Authors

  • Yaeko Nakajima-Takagi,

    1. Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan
    2. Japan Science and Technology Corporation, Core Research for Evolutional Science and Technology, Chiyoda-ku, Tokyo, Japan
    Search for more papers by this author
  • Mitsujiro Osawa,

    1. Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan
    2. Japan Science and Technology Corporation, Core Research for Evolutional Science and Technology, Chiyoda-ku, Tokyo, Japan
    Search for more papers by this author
  • Atsushi Iwama

    Corresponding author
    1. Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan
    2. Japan Science and Technology Corporation, Core Research for Evolutional Science and Technology, Chiyoda-ku, Tokyo, Japan
    • Correspondence to: Atsushi Iwama, M.D. Ph.D., 1–8-1 Inohana, Chuo-ku, Chiba, 260-8670 Japan. Fax: +81-43-226-2191. E-mail: aiwama@faculty.chiba-u.jp

    Search for more papers by this author

ABSTRACT

Hematopoietic stem cells (HSCs) are defined by their capacity to self-renew and to differentiate into all blood cell lineages while retaining robust capacity to regenerate hematopoiesis. Based on these characteristics, they are widely used for transplantation and gene therapy. However, the dose of HSCs available for use in treatments is limited. Therefore, extensive work has been undertaken to expand HSCs in culture and to produce HSCs from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) in order to improve the efficiency and outcome of HSC-based therapies. Various surface markers have been characterized to improve the purification of HSCs and a huge number of cytokines and small-molecule compounds have been screened for use in the expansion of HSCs. In addition, attempts to generate not only HSCs but also mature blood cells from ESCs and iPSCs are currently ongoing. This review covers recent approaches for the purification, expansion or production of human HSCs and provides insight into problems that need to be resolved. Anat Rec, 297:111–120. 2013. © 2013 Wiley Periodicals, Inc.

Ancillary